Adding radiation to second-line treatment for advanced bile duct cancer
Part of Cancer clinical trials.
This study tests whether adding radiation therapy to your second round of cancer treatment can help control intrahepatic cholangiocarcinoma that has spread to a few places. The goal is to slow cancer growth and improve outcomes compared to treatment without radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have intrahepatic cholangiocarcinoma (a type of bile duct cancer inside the liver) that has spread and cannot be removed by surgery.
- Your cancer must have progressed after your first round of standard treatment (like chemotherapy).
- You must have 5 or fewer total spots of cancer spread, with no more than 3 in any one organ (like the lungs or liver).
- All cancer spots must be safe to treat with radiation, and none of them can have been treated with radiation, surgery, or ablation (heat or cold treatment) before.
- You must be generally healthy: able to do light activity, with adequate blood counts, liver and kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining chemotherapy with radiation after surgery can help prevent the return of intrahepatic cholangiocarcinoma, a type of bile duct cancer. It is for people whose surgery showed a narrow margin or cancer in nearby lymph nodes.
This study tests a new oral medication (tinengotinib) against standard chemotherapy for people with advanced bile duct cancer that has a specific gene change (FGFR2). Doctors want to see if this drug can help shrink or slow the cancer better than current treatments.
This trial tests a new combination of drugs for people with advanced bile duct cancer that cannot be removed by surgery. Combining immunotherapy with chemotherapy may help shrink tumors and slow the cancer's growth.
This trial tests a combination of targeted therapy, immunotherapy, and a liver-directed procedure (like chemoembolization) versus a standard chemotherapy cocktail for a type of bile duct cancer that is confined to the liver. It aims to see if the new combo can help patients live longer or slow the cancer down.
This trial is testing a combination of two drugs (one that helps the immune system fight cancer and one that blocks blood vessel growth) with a special chemotherapy given directly into the liver. The goal is to shrink the tumor so it can be removed with surgery, possibly improving the chances of a cure.
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can improve outcomes for people with intrahepatic cholangiocarcinoma that can be surgically removed. It's for patients who haven't had prior treatment for their cancer and are in good overall health.
Hear when a new Intrahepatic Cholangiocarcinoma (Icc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.